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Abstract
Introduction: Tamsulosin, a selective a1-adrenergic receptor (a1-AR) antagonist, is a widely prescribed first-line
agent for benign prostatic hypertrophy (BPH). Its interaction with anesthetic agents has not been described.
Case presentation: We report the case of 54-year-old Asian man undergoing elective left thyroid lobectomy. The
only medication the patient was taking was tamsulosin 0.4 mg for the past year for BPH. He developed persistent
hypotension during the maintenance phase of anesthesia while receiving oxygen, nitrous oxide and 1% isoflurane.
The hypotension could have been attributable to a possible interaction between inhalational anesthetic and
tamsulosin.
Conclusion: Vigilance for unexpected hypotension is important in surgical patients who are treated with selective
a1-AR blockers. If hypotension occurs, vasopressors that act directly on adrenergic receptors could be more
effective.
Introduction
Tamsulosin (benzenesulfonamide) is a uroselective a1A-
adrenergic receptor (a1A-AR) antagonist primarily used
for patients with benign prostatic hyperplasia (BPH) pre-
senting with lower urinary tract symptoms [1]. The
recommended dose is 0.4 mg or 0.8 mg with a half-life of
nine to 15 hours. It is extensively metabolized by the liver.
Currently, a1-adrenergic receptor (a1-AR) antagonists
a r ec o m m o n l yp r e s c r i b e db yp h y s i c i a n sa sf i r s t - l i n e
agents to treat BPH, a common condition of aging men.
a1-AR antagonists exert their effects by blocking a1-AR-
mediated contraction of the prostatic smooth muscle
cells and bladder neck [2]. There are three a1-AR sub-
types: a1A, a1B and a1D. Terazosin, doxazosin and alfu-
zosin are a1-AR antagonists that show equal affinity for
all a1-AR subtypes [3]. Tamsulosin does not interfere
with blood pressure control and has a low potential to
cause vasodilation [4]. It is selective for a1A-and a1D-AR
subtypes but has less affinity for the a1B subtype.
Case presentation
A 54-year-old, 80-kg Asian man was scheduled for left
thyroid lobectomy for a thyroid nodule. He was
clinically euthyroid with normal thyroid function test
results. The patient’s medical history was insignificant
except for BPH. His New York Heart Association classi-
fication was class I. For BPH, he was being treated with
tamsulosin 0.4 mg at night for one year. He was a smo-
ker and had been smoking approximately 20 cigarettes a
day for the past 24 years. He had no known history of
allergy to any drug. He consented to general anesthesia
for thyroid lobectomy.
Before induction of anesthesia, the patient’sr e c o r d e d
blood pressure (BP) was 137/88 mm Hg, heart rate was
72 bpm, and temperature was 36.5°C. Cefazolin 1 g was
administered intravenously (IV) in the operating room
without any adverse effects. After placement of routine
monitors and preoxygenation, general anesthesia was
induced with sodium thiopentone 5 mg/kg, pethidine
1 mg/kg and atracurium 0.5 mg/kg, and the patient’s
trachea was intubated with a reinforced endotracheal
tube without any difficulty. The lungs were ventilated
with a controlled mode of ventilation with O2/N2Oa n d
1% isoflurane. The two BP readings taken after induc-
tion were 110/70 and 100/64 mm Hg. After laryngo-
scopy, the patient’s maximum BP reading was 162/96
mm Hg, and his heart rate was 104 beats/min. Within
10 minutes, the patient’s BP decreased to 75/45 mm Hg
despite a rapid infusion of 1 L of lactated Ringer’s
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oxygen saturation was between 98% and 99%. End-tidal
carbon dioxide remained between 33 and 36 mm Hg,
with a respiratory rate of 10 breaths/min. Ephedrine 30
mg in divided IV doses only transiently improved the
hypotension (BP to 85/40 mm Hg), and frequent pheny-
lephrine boluses (100 μg/bolus) were required to main-
tain systolic BP above 90 mm Hg. The patient’ss k i n
was warm but not diaphoretic. Skin erythema, urticaria,
bronchospasm, facial edema and other features of a
potential anaphylaxis or anaphylactoid reaction were
absent. No ischemic changes were observed on a three-
lead electrocardiogram (ECG). General anesthesia was
maintained with O2/N2O and isoflurane minimum
alveolar concentration (MAC) of 0.8%. At this point, the
differential diagnosis of hypotension was primarily direc-
ted to deep anesthesia or hypovolemia. While these were
being addressed, the surgeon was allowed to proceed.
There was continuing hypotension requiring pheny-
lephrine. At the time of surgical incision, the patient
moved slightly in response to surgical stimulation. The
total duration of surgery was 180 minutes (three hours),
and the total estimated blood loss was 70 mL. A total of
1200 μg of phenylephrine was required to maintain the
systolic a BP above 90 mm Hg throughout surgery.
At the end of surgery, isoflurane was turned off, and
the patient’s BP increased to 110/70 mm Hg with a
heart rate of 75 bpm. The patient completely recovered
from neuromuscular blockade after administration of
0.2 mg of glycopyrrolate and 2.5 mg of neostigmine.
The patient’s trachea was then extubated, and he was
shifted to the postanesthesia care unit. He remained in
the recovery room for two hours and remained hemo-
dynamically stable with BP in the range of 120/75 to
140/80 mm Hg and heart rate between 70 and 76 bpm.
Discussion
BPH is common among older men, with approximately
25% of men being affected after 40 years of age [5]. His-
tologic evidence of the disease is noted in 8% of men in
their 30 s, and the prevalence rapidly increases to more
than 70% after the age 60 years [6].
All a1-adrenoceptor antagonists have a similar efficacy
in improving symptoms and urinary flow. Many of these
agents were initially developed and approved for the
treatment of patients with hypertension until the devel-
opment of tamsulosin. Tamsulosin is a more selective
a1A subtype antagonist, which maintains the a-antago-
nist effect on the prostatic capsule and bladder neck but
has less of an effect on the vascular system and BP.
Tamsulosin is not indicated in the treatment of patients
with hypertension.
A meta-analysis related to the vascular-related safety
profile of a1 antagonists was carried out by Nickel et al [7].
They concluded that patients administered alfuzosin, tera-
zosin and doxazosin showed a statistically significant
increased risk of developing vascular-related events (dizzi-
ness, hypotension or syncope) compared with those taking
placebo. Tamsulosin showed only a numerical increase
that was not statistically significant.
A MEDLINE search from 1997 to the present revealed
no report of any adverse hemodynamic consequences of
tamsulosin interaction under anesthesia. Tamsulosin
drug interactions have been studied in humans; the use
of tamsulosin with nifedipine, enalapril, atenolol, furose-
mide or digoxin does not require dosage modification
when tamsulosin is initiated concomitantly with these
agents [8,9]. Tamsulosin is contraindicated with other
a1 antagonist and verapamil, which has a1-adrenoceptor
antagonist effects in therapeutic doses [10]. It is contra-
indicated in patients with orthostatic hypotension.
This case may illustrate a drug interaction between
tamsulosin and inhalational anesthetic agents. Isoflurane
is the most likely anesthetic drug to have interacted
because the phenylephrine requirement lasted until the
end of the case, and the hypotension resolved when iso-
flurane was stopped. The hypotension in this patient
may have been caused by chronic use of tamsulosin. Iso-
flurane is a known vasodilator and may have synergetic
effect with tamsulosin. This may explain why ephedrine
was less effective than phenylephrine in counteracting
hypotension. Whereas phenylephrine is a pure a1-AR
agonist, ephedrine has both central and peripheral
effects. In the clinical doses administered, its peripheral
effects may be less than those of phenylephrine. Ephe-
drine was administered initially because the differential
diagnosis considered at that time was either excessive
depth of anesthesia or hypovolemia. When a synergetic
effect was suspected, phenylephrine was used instead.
The point that negated vasodilation caused by an inap-
propriate depth of anesthesia was that the patient was
receiving less than 1 MAC of isoflurane, and he moved
in response to surgical stimulation at the time of inci-
sion. Hypovolemia was ruled out when the BP did not
rise after administration of 1 L of crystalloid.
The degree of hypotension was exceptional compared
with the concentration of anesthetic agent used. The
other differential diagnosis for this vasodilated hypoten-
sive state included anaphylaxis and myocardial ischemia.
Because the patient did not have any other features of
anaphylaxis and had a subsequent negative ECG result
for ischemia, these alternative diagnoses were rejected.
Other anesthetic drugs used in this patient were
thiopentone, pethidine and atracurium. Pethidine and
atracurium can both cause histamine release, but no
additional clinical signs of histamine release were appar-
ent in this patient. The dramatic increase in BP when
isoflurane was turned off goes in favor of some kind of
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to isoflurane cannot be ruled out completely.
As a result of the recent increase in prescriptions of
tamsulosin for aging men with BPH, hypotension under
anesthesia associated with this drug may occur. To
remove tamsulosin from the circulation would require
days of abstinence because tamsulosin has a long half-
life of nine to 15 hours.
Conclusion
This case reports hypotension in a patient on tamsulosin
under general anesthesia with N2O/O2,a t r a c u r i u ma n d
isoflurane anesthesia. Other factors may have contribu-
ted to the decreased BP, and tamsulosin cannot be
implicated definitively. This case nevertheless demon-
strates the importance of vigilance for unexpected hypo-
tension in patients taking tamsulosin. If hypotension
does develop in these patients, a direct-acting vasopres-
sor such as phenylephrine should be used.
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